Treatment of Classic Hairy-Cell Leukemia Requiring Therapy — No Active Infection, No Renal Impairment

Classic hairy-cell leukemia (HCL) at the point of treatment indication can follow the standard first-line pathway when two key conditions are met: the absence of an active infection and the absence of renal impairment. Both criteria directly determine which therapeutic approach is appropriate.

Clinical Scenario

Classic hairy-cell leukemia requiring treatment, with no active infection and no renal impairment present — the eligibility criteria that unlock the standard treatment algorithm.

Therapeutic Approach

When active infection and renal impairment are absent, the standard regimen centres on a purine nucleoside analog. The specific agent options, schedules, and routes of administration are outlined in the full structured protocol.

Treatment Goals

Near normalization of peripheral blood counts — hemoglobin, platelets, and absolute neutrophil count
Regression of splenomegaly on physical examination
Absence of morphologic HCL evidence on peripheral blood smear and bone marrow examination, assessed at 6 months

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1182/blood-2016-01-689422

In the absence of renal impairment or active infection, therapy should consist of a standard regimen of a purine nucleoside analog (either cladribine or pentostatin).

View source ↗